Clinical Core - Pharmacogenomics of Statin Therapy (POST)

临床核心 - 他汀类药物治疗的药物基因组学 (POST)

• 批准号: 9326329
• 负责人: Carlos Iribarren
• 金额: $ 38.56万
• 依托单位: CHILDREN'S HOSPITAL & RES CTR AT OAKLAND
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9326329
• 关键词: Adopted; Adult; Adverse effects; Aging; Biomedical Research; California; Caring; Cell model; Clinical; Clinical Research; Collection; Computerized Medical Record; Coronary; DNA; Data; Data Analytics; Data Set; Diabetes Mellitus; Disease; Electronic Health Record; Environment; Event; Exposure to; Feces; Future; Genes; Genotype; Group Practice; Guidelines; Health; Human; In Vitro; Individual; Informatics; Lipids; Medical; Metabolic; Molecular; Myopathy; Participant; Patients; Pharmacogenomics; Pharmacologic Substance; Pharmacy facility; Plasma; Population; Population Heterogeneity; Prospective cohort study; Recording of previous events; Records; Recruitment Activity; Research; Resources; Role; Sampling; Simvastatin; Site; Standardization; Stroke; Study Subject; System; Variant; Whole Blood; adverse outcome; base; biobank; c new; clinical practice; cohort; database query; design; epidemiology study; ethnic diversity; exome; follow-up; genetic analysis; genetic epidemiology; genetic information; genome wide association study; genome-wide; health care delivery; healthy aging; lymphoblastoid cell line; member; phenotypic data; programs; racial diversity; response; socioeconomics; transcriptomics

CLINICAL CORE: PROJECT SUMMARY The Clinical Core at the Division of Research, Kaiser Permanente of Northern California (KPNC) is a key component of the overall POST Center. It serves a vital role by providing all the human participants for Project 1, and all the genotypic data, phenotypic data, and DNA samples to Project 3. The aims of the POST Clinical Core are: 1) To obtain whole blood and plasma from KPNC statin users with a) a major adverse coronary event (MACE, N=124) while on treatment, b) statin-induced myopathy (N=124), c) new onset diabetes (N=124), and d) three sets of 124 matched controls (N=372) for the studies in Project 1 (“Molecular Determinants of Statin Efficacy and Adverse Effects using Cellular Models”, Drs. Medina and Krauss); 2) With Project 3 (“Genome-wide Association Study of Statin Response and its Consequences”, Dr. Risch), create a dataset of medical and pharmacy information relevant to statin effects on lipids, MACE, stroke, statin-induced myopathy and new onset diabetes from the electronic medical records of patients in the GERA cohort; and 3) Provide DNA samples from selected statin users within the GERA cohort (n=2,517) and within the extended Kaiser Permanente Research Program on Genes, Environment, and Health (RPGEH) biorepository (n=843) to Project 3 for follow-up genetic analysis of candidate loci identified throughout the Center's research program.

临床核心：项目总结 北加州Kaiser Permanente研究部的临床核心是一个关键 整个邮政中心的组成部分。它通过为项目提供所有人类参与者，发挥着至关重要的作用 1，以及所有的基因数据、表型数据和DNA样本到项目3。后临床的目标 核心是：1)获取患有a)主要不良冠状动脉病变的KPNC他汀类药物使用者的全血和血浆 事件(MACE，N=124)，b)他汀类药物引起的肌病(N=124)，c)新发糖尿病 (n=124)，以及d)三组124个匹配的对照(N=372)，用于项目1(分子)的研究 使用细胞模型的他汀类药物疗效和不良反应的决定因素“，Medina和Krauss博士)；2) 项目3(“他汀类药物反应及其后果的全基因组关联研究”，Risch博士)，创建了一个 与他汀类药物对血脂、MACE、中风、他汀类药物诱导的影响相关的医疗和药学信息数据集 GERA队列患者的电子病历中的肌病和新发糖尿病；以及3) 提供GERA队列(n=2,517)和扩展的 凯撒永久基因、环境和健康研究计划(RPGEH)生物库(n=843) 项目3，对中心整个研究计划中确定的候选基因座进行后续遗传分析。